Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia

British Journal of Haematology - Tập 137 Số 5 - Trang 461-467 - 2007
Sergio Giralt1, Mukta Arora2, John M. Goldman3, Stephanie J. Lee4, Richard T. Maziarz5, Philip L. McCarthy6, Kathleen A. Sobocinski7, Mary M. Horowitz7
1M.D. Anderson Cancer Center, Houston, TX
2University of Minnesota, Minneapolis, MN
3National Institute of Health, Bethesda, MD
4Fred Hutchinson Cancer Research Center, Seattle, WA
5Oregon Health & Science University, Portland, OR
6Roswell Park Cancer Institute, Buffalo, NY
7Center for International Blood and Marrow Transplant Research (CIBMTR), Health Policy Institute, Medical College of Wisconsin, Milwaukee, WI, USA

Tóm tắt

SummaryThe discovery and approval of imatinib drastically changed the therapeutic algorithm for chronic myeloid leukaemia (CML). Imatinib is now considered the therapy of choice for patients with newly diagnosed CML, including those previously considered candidates for allogeneic haematopoietic cell transplantation (HCT). We compared numbers and types of allogeneic HCTs performed for CML in North America before and after the introduction of imatinib, and publication of the International Randomized Trial of Interferon and STI571 (IRIS) using transplants reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The number of HCTs for CML registered with the CIBMTR in 1998 was 617; 62% were performed in first chronic phase (CP1). Only 1% of patients had received imatinib prior to transplantation. In 2003, the number of HCTs reported was 223; 44% were performed in CP1 and 77% of patients received imatinib prior to transplantation. The introduction of imatinib therapy has had a profound impact on the use of allogeneic transplantation for CML, with a marked decrease in the number of transplants for CML and an accompanying decrease in the proportion done in CP1. Most patients now receive a trial of imatinib before proceeding to HCT.

Từ khóa


Tài liệu tham khảo

10.1053/bbmt.2002.v8.pm12374452

10.1182/blood-2006-02-005686

10.1182/blood.V98.10.3074

Chomel J.C., 2000, Persistence of BCR‐ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon‐alpha therapy or allogeneic bone marrow transplantation, Blood, 95, 404, 10.1182/blood.V95.2.404

10.1182/blood-2004-09-3544

10.1182/asheducation-2005.1.174

Druker B., 1999, Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia, Blood, 94, 368a

10.1056/NEJM200104053441401

10.1056/NEJM200104053441402

10.1182/blood.V94.2.384

Giles F., 2004, A phase I/II Study of AMN107, a novel aminophyrimidine inhibitor of Bcr‐Abl, on a continuous daily dosing schedule in adult patients (pts) with imatinib‐resistant advanced phase chronic myeloid leukemia (CML) or relapsed/refractory Philadelphia chromosome (Ph+) acute lymphocytic leukemia (ALL), Blood, 104, 10a, 10.1182/blood.V104.11.22.22

Giralt S.A., 1993, Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia, Journal of Clinical Oncology, 11, 1055, 10.1200/JCO.1993.11.6.1055

10.1182/blood.V98.7.2039

Gratwohl A., 2006, Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long‐term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT), Haematologica, 91, 513

10.1056/NEJM199804023381405

10.1182/blood.V77.4.874.874

10.1002/1097-0142(20001015)89:8<1647::AID-CNCR1>3.0.CO;2-U

10.1056/NEJMoa011573

10.1002/cncr.11381

Kantarjian H.M., 2003, Quantitative polymerase chain reaction monitoring of BCR‐ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic‐phase chronic myelogenous leukemia, Clinical Cancer Research, 9, 160

10.1182/blood-2004-02-0711

10.1182/blood-2003-11-3800

10.1200/JCO.1998.16.4.1526

10.1200/JCO.1998.16.9.2897

10.1182/blood.V92.11.4047.423a04_4047_4052

10.1182/blood.V98.12.3205

10.1056/NEJMoa022457

10.1182/blood-2003-02-0371

10.1182/blood-2002-02-0535

10.1182/blood-2004-04-1674

10.1182/blood-2002-08-2619

10.1038/sj.bmt.1705190

Silver R.T., 1999, An evidence‐based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology, Blood, 94, 1517

Talpaz M., 2004, Hematologic and cytogenetic responses in imatinib‐resistant accelerated and blast phase chronic myeloid leukemia (CML) patients treated with the dual SRC/ABL kinase inhibitor BMS‐354825: results from a phase I dose escalation study, Blood, 104, 10a, 10.1182/blood.V104.11.20.20

10.1182/blood.V99.6.1971

Thông tin
Thông tin xuất bản

British Journal of Haematology

Tập 137 Số 5

461-467

Thông tin tác giả